Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CROSS RESISTANCE AND COLLATERAL SENSITIVITY STUDIES IN CANCER CHEMOTHERAPY.

Literature DB >> 14153767

CROSS RESISTANCE AND COLLATERAL SENSITIVITY STUDIES IN CANCER CHEMOTHERAPY.

Abstract

Keywords: ALKYLATING AGENTS; ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; AZASERINE; COLCHICINE; DRUG RESISTANCE, MICROBIAL; FOLIC ACID ANTAGONISTS; GUANIDINES; LEUCINE; METABOLISM; NEOPLASM THERAPY; NEOPLASMS, EXPERIMENTAL; PHARMACOLOGY; PURINES; PYRIMIDINES; REVIEW; STEROIDS; TISSUE CULTURE

Mesh：

Substances：

Year: 1963 PMID： 14153767 DOI： 10.1016/s0065-230x(08)60984-7

Source DB: PubMed Journal: Adv Cancer Res ISSN： 0065-230X Impact factor: 6.242

Keyword Cloud
Cited

× No keyword cloud information.

16 in total

1. Cytotoxicity of nimbolide towards multidrug-resistant tumor cells and hypersensitivity via cellular metabolic modulation.

Authors: Nuha Mahmoud; Mohamed E M Saeed; Yoshikazu Sugimoto; Sabine M Klauck; Henry J Greten; Thomas Efferth
Journal: Oncotarget Date: 2018-11-06

2. [ON THE MORPHOLOGICAL EFFECT OF DIFFERENT CHEMOTHERAPEUTIC AGENTS ON DEGRANOL-SENSITIVE AND DEGRANOL-RESISTANT NK/LY ASCITES TUMOR].

Authors: E GATI
Journal: Z Krebsforsch Date: 1965-02-03

3. Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.

Authors: Marco Barazas; Alessia Gasparini; Yike Huang; Asli Küçükosmanoğlu; Stefano Annunziato; Peter Bouwman; Wendy Sol; Ariena Kersbergen; Natalie Proost; Renske de Korte-Grimmerink; Marieke van de Ven; Jos Jonkers; Gerben R Borst; Sven Rottenberg
Journal: Cancer Res Date: 2018-12-10 Impact factor: 12.701

4. With great power comes great vulnerability.

Authors: Rodrigo Leite de Oliveira; Liqin Wang; Rene Bernards
Journal: Mol Cell Oncol Date: 2018-10-09

5. Taking advantage of drug resistance, a new approach in the war on cancer.

Authors: Liqin Wang; Rene Bernards
Journal: Front Med Date: 2018-07-18 Impact factor: 4.592

6. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.

Authors: Mareike Berlak; Elizabeth Tucker; Louis Chesler; Johannes Hubertus Schulte; Mathurin Dorel; Annika Winkler; Aleixandria McGearey; Elias Rodriguez-Fos; Barbara Martins da Costa; Karen Barker; Elicia Fyle; Elizabeth Calton; Selma Eising; Kim Ober; Deborah Hughes; Eleni Koutroumanidou; Paul Carter; Reda Stankunaite; Paula Proszek; Neha Jain; Carolina Rosswog; Heathcliff Dorado-Garcia; Jan Jasper Molenaar; Mike Hubank; Giuseppe Barone; John Anderson; Peter Lang; Hedwig Elisabeth Deubzer; Annette Künkele; Matthias Fischer; Angelika Eggert; Charlotte Kloft; Anton George Henssen; Michael Boettcher; Falk Hertwig; Nils Blüthgen
Journal: Mol Cancer Date: 2022-06-10 Impact factor: 41.444

CROSS RESISTANCE AND COLLATERAL SENSITIVITY STUDIES IN CANCER CHEMOTHERAPY.

1. Cytotoxicity of nimbolide towards multidrug-resistant tumor cells and hypersensitivity via cellular metabolic modulation.

2. [ON THE MORPHOLOGICAL EFFECT OF DIFFERENT CHEMOTHERAPEUTIC AGENTS ON DEGRANOL-SENSITIVE AND DEGRANOL-RESISTANT NK/LY ASCITES TUMOR].

3. Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.

4. With great power comes great vulnerability.

5. Taking advantage of drug resistance, a new approach in the war on cancer.

6. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.

7. Mutagenic studies of folic acid antagonists.

8. Cross-resistance and collateral susceptibility to antifolic antimalarial compounds.

9. FOLIC ACID METABOLISM IN ANTIFOLIC-RESISTANT MUTANTS OF STREPTOCOCCUS FAECALIS.

Review 10. Toward personalized treatment approaches for non-small-cell lung cancer.